Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies

13 May 2020

Abstract excerpt

Drug combinations that target critical pathways are a mainstay of cancer care. To improve current approaches to combination treatment of chronic lymphocytic leukemia (CLL) and gain insights into the underlying biology, we studied the effect of 352 drug combination pairs in multiple concentrations by analysing ex vivo drug response of 52 primary CLL samples, which were characterized by "omics" profiling. Known...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32404973
DOI: 10.1038/s41375-020-0846-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependenciesPMID 32404973Read ↗

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.Semantic proximity Read ↗

SYNERGxDB: an integrative pharmacogenomic portal to identify synergistic drug combinations for precision oncology.Semantic proximity Read ↗

A statistical framework for defining synergistic anticancer drug interactionsSemantic proximity Read ↗

Deciphering molecular mechanisms of synergistic growth reduction in kinase inhibitor combinationsSemantic proximity Read ↗

Methods for High-Throughput Drug Combination Screening and Synergy ScoringSemantic proximity Read ↗

Combinatorial drug-microenvironment interaction mapping reveals cell-extrinsic drug resistance mechanisms and clinically relevant patient subgroups in CLLSemantic proximity Read ↗

Anticancer Target Combinations: Network-Informed Signaling-Based Approach to DiscoverySemantic proximity Read ↗

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cellsSemantic proximity Read ↗

Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling.Semantic proximity Read ↗

Network-based Computational Drug Combination PredictionSemantic proximity Read ↗

A cancer pharmacogenomic screen powering crowd-sourced advancement of drug combination predictionSemantic proximity Read ↗

Synergistic drug combinations from electronic health records and gene expressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.